Optigenex Inc. Renews Its Agreement With RFI Ingredients for Marketing and Sale of AC-11(R) in Retail and Direct to Physician Channels (Financial Terms Were Not Disclosed) 8:00a ET February 18, 2010 (Market Wire) Optigenex Inc. (PINKSHEETS: OPGX) announced today the signing with RFI, LLC of a new, non-exclusive Supply and Trademark License Agreement for the territory of North America. The new agreement renews the parties' several year-long business relationship and extends continuing rights to RFI to manufacture and market dietary supplement products containing AC-11(R) (formerly known as C-Med-100(R)). Both parties anticipate that this timely recommitment will reap mutual benefits, as the growing body of AC-11(R) scientific validation recently has opened several new doors for capitalizing on Optigenex's patented technology, especially in the novel field of advanced, oral-based sun care products.
Jeff Wuagneux, President and CEO of RFI, stated, "We are very excited to continue our work with the management of Optigenex to promote the AC-11(R) product into the natural healthcare industry. Over the past several years we have come to value the science behind AC-11(R), and Optigenex's commitment to furthering the clinical validation of the technology. RFI is dedicated to promoting and marketing science based products, and we feel confident that AC-11(R) will have a great impact as a key strategic component in both the oral-based sun care market, as well as the DNA repair and antioxidant categories."
Daniel Zwiren, President and CEO of Optigenex, added, "We are pleased with the opportunity to renew our excellent relationship with RFI. Jeff and his team have demonstrated an impressive understanding and command of the market, as well as a strong loyalty to AC-11(R) technology over the past two years in the direct to physician's channel. The signing of this expanded agreement was an easy decision for us, because RFI in an impressive fashion has grown its business vertically from wholesale ingredient supplier to a finished product, direct to consumer marketing company. We are confident that RFI is positioned to market AC-11(R) on a large scale to health conscious, educated consumers in North America."
About RFI, LLC:
RFI, LLC is a U.S. based (New York, Colorado) Life Science Development and Commercialization Company offering a pipeline of novel compounds and proprietary science-based nutritional bioactive formulas for the food, dietary supplement, practitioner, direct selling and direct to consumer marketing channels.
About Optigenex Inc.:
Optigenex Inc. is a formulator, distributor and provider of proprietary next generation skin care technology, dietary supplements and bulk ingredient featuring AC-11(R) as its core product. AC-11(R) (formerly known as C-MED-100(R)) is a patented, bioactive and water soluble rain forest compound derived from the medicinal herb Uncaria tomentosa. For more information about Optigenex please visit our website: www.optigenex.com
*The statements made in this press release have not been evaluated by the Food and Drug Administration (FDA). The products mentioned herein are not intended to diagnose, treat, cure or prevent any disease.
Dan Zwiren President and CEO Optigenex Inc. dzwiren@optigenex.com 201 355 2098
posted
This volume is rediculous with not a single move. Imagine 1,056,253,647, just for today and it's 2.23 P.M.CST. What is going on. I am thinking by the time the market is over, it will top what I have stated.
IP: Logged |
posted
I think some big time dilution is going on. The volume is up a gain today. Much bigger than yesterday, 1,522,114,340 for crying out loud.
IP: Logged |
posted
News 3-23-10 Optigenex Inc. Grants Solgar Vitamin and Herb New Rights to Market AC-11(R) in Vitamin, Health and Specialty Food Retail Channels in the U.S. and Overseas 8:02a ET March 23, 2010 (Market Wire) Optigenex, Inc. (PINKSHEETS: OPGX) announced today that Solgar Vitamin and Herb has been granted new rights to market and distribute dietary supplements containing Optigenex's patented ingredient AC-11(R) in health food, vitamin and specialty food stores worldwide, excluding certain geographic areas. Financial and other terms have not been disclosed. Today's announcement signals the renewal of a cooperative business relationship between the parties that first began in 2007.
AC-11(R) by Optigenex, the first all natural product that actually helps the body to enhance its own ability to repair DNA damage caused by overexposure to the sun and oxidative stress, is in products currently sold in the United States, Canada and worldwide by over 100 companies in the cosmetic, personal care and nutraceutical industries. Optigenex technology is protected by six patents in the United States, with additional patents pending in the United States and other key economic centers globally.
Solgar is a manufacturer and provider of nutritional supplements with over 60 years of experience in the health and wellness field. The company is recognized worldwide for its industry leading experts, as well as its own, state of the art manufacturing and quality assurance laboratory facilities.
Daniel Zwiren, president and CEO of Optigenex, said, "Our company is pleased by Solgar's enthusiasm for AC-11(R). Solgar has a superior reputation among retailers and consumers and, as such, provides excellent exposure for our unique, patented technology. We feel that Solgar's commitment to innovative, science-based formulations and consumer education fits hand in glove with the growing body of data supporting AC-11(R)'s role in promoting healthy, all natural DNA repair. Through Solgar and our other invaluable channel partners, Optigenex believes the message behind AC-11(R) will reach the widest possible cross section of educated consumers."
About Optigenex Inc.:
Optigenex Inc. is a formulator, distributor and provider of proprietary next generation skin care technology, dietary supplements and bulk ingredient featuring AC-11(R) as its core product. AC-11(R) (formerly known as C-MED-100(R)) is a patented, bioactive and water soluble rain forest compound derived from the medicinal herb Uncaria tomentosa. For more information about Optigenex please visit our website: www.optigenex.com
*The statements made in this press release have not been evaluated by the Food and Drug Administration (FDA). The products mentioned herein are not intended to diagnose, treat, cure or prevent any disease.
Dan Zwiren President and CEO Optigenex Inc. dzwiren@optigenex.com 201 355 2098
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
